Protocol Ledger

NCT03952806 · Phase III · COMPLETED

Study of BHV-3241 in Participants With Multiple System Atrophy

Interventional Phase III clinical trial protocol NCT03952806 sponsored by Pfizer in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-07-29 Enrollment: 421 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03952806
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)421 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03952806
Protocol FieldVerified Registry Value
NCT IdentifierNCT03952806
Consolidated Lead SponsorPfizer
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment421 participants (ACTUAL)
Registered Start Date2019-07-29
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI